SWITCH Study: Metabolic and weight effects of a switch to aripiprazole
The purpose of this study is to determine if subjects who switch from olanzpine, quetiapine or risperidone to aripiprazole show changes in body composition, weight, lipids, glucose, (and other metabolic markers), energy expenditure or caloric consumption after 14 weeks.
- Between 18-65 years of age, any race and either gender.
- Meets DSM IV criteria for a psychotic disorder (schizophrenia, schizophreniform, brief psychotic disorder, schizoaffective disorder).
- Antipsychotic monotherapy with olanzapine, risperidone or quetiapine for minimum of 1 month at entry into study and with weight gain of 1 BMI units while on this medication or development of abnormalities of glucose (greater than 110 mg/dl fasting), lipids (TC, HDL, TG, or LDL greater than 10% change) or blood pressure (greater than 20 mmHg change in systolic and diastolic)
- Antipsychotic monotherapy with aripiprazole is planned by the subject's treating psychiatrist.
- Subjects able to fully participate in the informed consent process
- Female subjects of childbearing potential must be using a medically accepted means of contraception which includes tubal ligation, hysterectomy, condoms, oral contraceptives, IUD, cervical cap, diaphragm, transdermal contraceptive patch, and abstinence.
- Subjects have had a previous trial of aripiprazole
- Subjects receiving other medications known to affect weight balance including depakote, lithium, tegretol, lamotragine, mirtazapine, corticosteroids and stimulants (i.e. methamphetamine) All concomitant medications will be reviewed by the study physician.
- Subjects are receiving over-the-counter weight loss medications or are actively involved with a weight loss program.
- Serious, unstable medical illness.
- At serious suicidal risk.
- Subjects with substance abuse or dependence.
- Subjects with an eating disorder.
- Female subjects who are either pregnant or nursing.
- Known history of mental retardation or dementia
Contact Information: If you think that you might be eligible for this study or if you would like more information, please contact Brenda Pearson, MSW, LCSW at 919-843-8084